The antibleeding drug Trasylol has been pulled from the market around the world after a study has shown there may be an increased risk of death from use. The drug is used during heart bypass surgery.
The announcement came as a Canadian study comparing the safety and efficacy of Trasylol with two others was halted. Preliminary results from that trial also suggested Trasylol increased the risk of death when compared with the other drugs. The trial was to include 3,000 patients.
Trasylol, also known as aprotinin, works by blocking enzymes that dissolve blood clots.
The FDA panel had met last month to discuss the drug but was advised to keep the drug on the market. Possible side effects from Trasylol include heart attack, stroke, and kidney problems.
For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.